Reuters logo
BRIEF-Endo Pharmaceuticals presents new mid-stage data evaluating safety and effectiveness of Xiaflex
September 30, 2016 / 11:46 AM / in a year

BRIEF-Endo Pharmaceuticals presents new mid-stage data evaluating safety and effectiveness of Xiaflex

Sept 30 (Reuters) - Endo International Plc

* Endo Pharmaceuticals presents new phase 2 data evaluating the safety and effectiveness of Xiaflex(collagenase clostridium histolyticum) for dupuytren’s disease nodules

* Safety profile of those treated with CCH was generally well tolerated

* Study participants treated with 1 injection of Xiaflex showed statistically significant decrease in size, hardness of dupuytren’s disease nodules

* One adverse event was reported as severe (injection site pain with CCH 0.60 mg)

* No patients were discontinued from study because of an adverse event. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below